Keros Therapeutics (NASDAQ: KROS - Get Free Report) and Upstream Bio (NASDAQ: UPB - Get Free Report)

Tax-loss selling is likely to lead these 20 stocks to become artificially depressed in the fourth qu

– Verekitug, 100 mg dosed every 12 weeks, reduced AAER by 56% compared to placebo in patients with s

HC Wainwright & Co. analyst Matthew Caufield reiterates Upstream Bio (NASDAQ:UPB) with a Buy

– Following productive FDA discussions, Upstream Bio will study 400 mg of verekitug administered eve

Fannie Mae Announces Sale of Non-Performing Loans PR Newswire WASHINGTON, Aug. 19, 2026

JP Morgan analyst Tessa Romero maintains Upstream Bio (NASDAQ:UPB) with a Neutral and raises the

Truist Securities analyst Danielle Brill maintains Upstream Bio (NASDAQ:UPB) with a Buy and lower

Upstream Bio, Inc. (UPB) came out with a quarterly loss of $0.73 per share versus the Zacks Consensu

Upstream Bio (NASDAQ:UPB) reported quarterly losses of $(0.73) per share which beat the analyst cons

Upstream Bio, Inc. (UPB) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism abo

Fannie Mae Announces the Results of its Thirty-sixth Reperforming Loan Sale Transaction PR Newswire

– Verekitug, administered once every three months, led to clinically meaningful improvements in nasa

– Verekitug, administered once every three months, led to clinically meaningful improvements in nasa

NEW YORK--(BUSINESS WIRE)-- #creditratingagency--KBRA assigns preliminary ratings to 65 classes of m

JP Morgan analyst Tessa Romero downgrades Upstream Bio (NASDAQ:UPB) from Overweight to Neutral an

Upstream Bio, Inc. (UPB) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Tra

Upstream Bio, Inc. (NASDAQ:UPB), a clinical-stage company developing treatments for inflammatory dis

WALTHAM, Mass., June 08, 2026 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage

HC Wainwright & Co. analyst Matthew Caufield initiates coverage on Upstream Bio (NASDAQ:UPB)

WALTHAM, Mass., June 03, 2026 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage

I am initiating a Buy rating on Verekitug, the lead asset of Upstream Bio, a small-cap biotech tradi

– Verekitug led to statistically significant and clinically meaningful improvement in asthma symptom

– Verekitug led to statistically significant and clinically meaningful improvement in asthma symptom

Mizuho analyst Joseph Catanzaro maintains Upstream Bio (NASDAQ:UPB) with a Outperform and lowers

Upstream Bio, Inc. (UPB) came out with a quarterly loss of $0.75 per share versus the Zacks Consensu

Upstream Bio (NASDAQ:UPB) reported quarterly losses of $(0.75) per share which beat the analyst cons

– Company rapidly advancing Phase 3 programs designed to deliver best-in-class efficacy with conveni

The presentations feature new data from the Phase 2 VIBRANT trial evaluating verekitug, the only kno

WALTHAM, Mass., April 17, 2026 (GLOBE NEWSWIRE) -- Upstream Bio, Inc.  (Nasdaq: UPB), a clinical-sta

Sanofi reports positive Phase 2 data for lunsekimig in asthma and nasal polyps, while atopic dermati

Evercore ISI Group analyst Cory Kasimov downgrades Upstream Bio (NASDAQ:UPB) from Outperform to I

U.S. stock futures down, Zenas Biopharma shares fall 9.5% in pre-market trading due to pricing of pu

Pre-Market Stock Futures: Futures are trading lower as we prepare to end another up-and-down week, a

The company reported a cash position of $341.5 million, expected to fund planned operations through

Upstream Bio outlines Phase 3 plans for verekitug as asthma and CRSwNP data support dosing strategy;

– Company to pursue Phase 3 development strategy designed to deliver best-in-class efficacy with a h